Clinical Research Directory
Browse clinical research sites, groups, and studies.
Exploratory Study of the Effects of Peptide PMS-001 on Long-Delay Recall in Patients With Moderate to Severe Dementia
Sponsor: Ruijin Hospital
Summary
This is a single-center, randomized, double-blind, placebo-controlled study. Patients will be randomly assigned to either the peptide intervention group (with dose escalation at 15mg, 30mg, 60mg, and 75mg) or the placebo control group. After learning and training, participants will receive an injection of PMS-001. The efficacy and safety of the intervention will be assessed at 1 hour, 1 day, 3 days, and 1 week post-intervention. This study aims to evaluate the effects of PMS-001 on improving long-delay recall in patients with moderate to severe dementia, as well as its safety profile.
Key Details
Gender
All
Age Range
60 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2025-08-01
Completion Date
2026-01-31
Last Updated
2025-05-01
Healthy Volunteers
No
Conditions
Interventions
Peptide PMS-001 Intravenous Injection
Participants will receive intravenous injections of PMS-001.
Placebo
The control group will receive a placebo, which is the blank excipient (mannitol) of the injectable PMS-001.
Locations (2)
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China